Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gap filled yesterday!! Let’s go!!!
Consolidated revenues for the Third Quarter were $6.0 million, an increase of approximately 20% as compared to revenues for the comparable quarter of the prior fiscal year. This marks the seventh consecutive quarter of year-on-year revenue growth during which the revenues grew an average of 122% per quarter on a year-on-year basis.
12,000,001
Mine is the same
Anyone know where the shareholder meeting is being held in June?
.40 would be nice!
Hi, Mark
You are correct.
There were three zeros left off when the voter instruction form was created. All the documents and SEC filings have the correct information.
The shareholders who received electronic delivery will see the correct information on Proxyvote.com shortly.
Shareholders who receive paper delivery will have the correct information on their voter instruction form.
As for the proposal, this is a revote on the proposal from the December 4, 2019 meeting, which was approved. I will be happy to discuss the reason for the need for the increase. This is also explained in the proxy. I have attached a copy of the document.
It is in the best interest of the stockholders to approve the increase. Primarily to have authorized shares underlying the Series J, and public companies need a cushion of authorized shares in their treasury.
Best regards,
Dianne
ELITE-PH-WEB GIF
Dianne Will
Investor Relations & Corporate Affairs
Elite Pharmaceuticals Inc.
165 Ludlow Avenue
Northvale, NJ 07647
Tel: 518-398-6222
E-Mail: Dianne@ElitePharma.com
This communication and any files transmitted with it contain information that is confidential and may be privileged and exempt from disclosure under applicable law. It is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient, you are hereby notified that any use, dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender. Thank you for your cooperation.
I see it on E trade as well.
I know it doesn’t make sense. It didn’t make sense back in 2008-09 either. One thing I’ve learned. Don’t fight the fed.
Right on schedule!
What would any CEO be doing right now? Typically trying to find the best outcome for the company. I’m not sure I understand the question. It seems self explanatory to me.
Doesn’t seem like it. It appears the price is moving up. Seems like some big blocks being purchased.
I heard it from the same source you got your info from.
That’s weird, I heard some in management are buying Elite shares.
I know right. It moves up and down all day. Pretty ridiculous to post a daily move.
Elite up 4.9%.
Looking good.
I was there an hour ago and the lot was full.
Yeah, sure, right. Why would they do that on a Monday?
Good news right around the corner.
You’re talking about the past. Look to the future. Great things are on the horizon.
Elite’s future looking great! Watch what happens next.
SequestOx is hardly dead. Press Release out today confirmed this for us.
This approval represents the first of many products being co-developed with our partner, SunGen," said Nasrat Hakim, President and CEO of Elite. "This is the fifth product approval for Elite in 2018 and we have three ANDAs still pending with the FDA in addition to our SequestOx™ NDA filing."
You’re definitely good.
Excitement is right!
Per the end of the conference call:
Keeping watching for Elite, we have a lot of news, good news coming between now and the end of the year. As I told you, we are expecting a filing soon, an announcement hopefully of launch for sales from marketing among others. Quite a exciting time between now and the end of the year. This concludes this earning call. Thank you
I didn’t get the sense of low energy at all. Here’s the way he concluded the conference call:
And that was the last question. Keeping watching for Elite, we have a lot of news, good news coming between now and the end of the year. As I told you, we are expecting a filing soon, an announcement hopefully of launch for sales from marketing among others. Quite a exciting time between now and the end of the year.
Exciting is not low energy.
I see you are connecting the dots also.
That’s just baloney.
Baloney
What a load of shit!
That’s a load of shit
Really? That’s your argument? Hey, can aspirin be abused by taking more pills at the same time? C’mon.
Here’s the full press release. Get real.
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss Third Quarter Financial Results on February 12, 2018
Financials for Third Quarter Fiscal Year 2018 Ended December 31, 2017 will be released on February 9, 2018
NORTHVALE, N.J., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that the third quarter financial results of the 2018 fiscal year will be released on Friday, February 9, 2018. Elite's management will host a live conference call on Monday, February 12th at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Stockholder questions should be submitted to the company in advance of the call.
Conference Call Information
Date: February 12, 2018
Time: 11:30 AM EST
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com by 8:00 PM EST on Friday, February 9, 2018
Audio Replay: http://ir.elitepharma.com/events_presentations
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy's Laboratories and Valeant Pharmaceuticals International. Elite currently has nine commercial products being sold, four products filed with the FDA, additional approved products pending manufacturing site transfer and the NDA filing for SequestOx™. Elite's lead pipeline products include abuse-deterrent opioids which utilize the Company's patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, Elite's ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of SequestOx™ by the FDA, and the actions the FDA require of Elite in order to obtain approval of the NDA. These forward-looking statements are not guarantees of future action or performance. These risks and other factors, including, without limitation, Elite's ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
Primary Logo
Feb 07, 2018
That’s ridiculous. The number is on the website in black and white. Give me a break.
I seem to remember during the last conference call Nasrat stated SequestOx is still a top priority. Go back and listen for yourself.
Elite gained well over 5% today.
But on the bright side it could have been a lot more.
Lol
Are you tempted to short more again at .14? Too bad you didn’t even cover a single share before today. You could have saved yourself a few dollars.
You don’t have to wait. It already hit 10 cents.
.02 is baloney as stated during the last conference call. Go back and listen for yourself.
I think you need to check the chart again. The conference call started at 11:30 eastern time and then the price did nothing but rise during and after the call.
Hmm, that is a strange assertion. If you look at the chart, ever since the conference call at 11:30 eastern time the price has risen.